Stockchase-logo
Track Stocks Watchlist
Top Picks Today
=iconClose Home All Opinions Top Picks Stocks Experts Top Experts Panic-proof Top 100 Stocks Monthly gems News
Watchlist Track Stocks
Top Picks Today
Home » Stock Lists

Top Biotech and Pharma Stocks to Bet on Cancer Cure & Control

Melisa R. H. Posted On October 10, 2019
0
0
Shares
  • Share On Facebook
  • Tweet It

Cancer fighting drugs and therapy companies are poised to profit from long term aging trends of the population as well as the rise of cancer in general. There are now companies that are trying to personalize treatments with gene therapy.

Here are Canadian and US companies that are producing innovative methods to control and cure cancer.

👨‍⚕️ Healthcare

Canada Stocks

Oncolytics Biotech (ONC-T)
A company that specializes in treating solid tutors. There is still a long way to go but the product has huge potential.

Oncolytics Biotech (ONC-T) — Stockchase
Oncolytics Biotech (ONC-T) — Stockchase

Opinion about ONC-T: The technicals do not look good at all – with a decline lasting over the past two months. He would not touch this one at all. A 50 day moving average would be a buy signal if it can trade back above it.

stockchase.com stockchase.com

Concordia International Corp (CXR-T)
The company focuses on treating ADHD, cancer and asthma. They went through a restructuring, along with many other Canadian drug manufacturers.

Concordia International Corp (CXR-T) — Stockchase
Concordia International Corp (CXR-T) — Stockchase

Opinion about CXR-T: Likes turnarounds, but it’s not ready. Want to see two things: 1) the stock hitting a 52-week high, and 2) the numbers moving in the right direction. Don’t do anything until then. Odds are this is going to zero.

stockchase.com stockchase.com

Medx Health Corp. (MDX-X)
A company that has recently changed their President and CEO. It is a medical device manufacturer that helps diagnose skin cancer, and they are now entering Spanish-speaking countries.

Medx Health Corp. (MDX-X) — Stockchase
Medx Health Corp. (MDX-X) — Stockchase

Opinion about MDX-X: Brazilian order? He owns warrants and his wife works as a consultant for them. They have orders for 500 units for a melanoma testing product. The delivery is subject to approval by authorities in Brazil. This could lead to hardware sales by June and revenues that begin to show up in Q4.…

stockchase.com stockchase.com

U.S Stocks

Amgen Inc. (AMGN-Q)
A developer and manufacturer of biotechnology based therapy. They have several cancer fighting drugs in their repertoire including a new colorectal cancer drug. They have surpassed earning estimates in the last year and pays a dividend of 3%.

Amgen Inc. (AMGN-Q) — Stockchase
Amgen Inc. (AMGN-Q) — Stockchase

Opinion about AMGN-Q: Phase 2 drug in the GLP-1 space -- not as mature as LLY's drug, but you don't pay as much for this company either. Trades ~14x earnings, compared to 50x for LLY. And that's more his style of investing.

stockchase.com stockchase.com

Celgene Corp (CELG-Q)
An American biotech company that specializes in cancer and inflammatory disorder therapy. They are starting the process of merging with BMY-N. A good cash flow generator.

Celgene Corp (CELG-Q) — Stockchase
Celgene Corp (CELG-Q) — Stockchase

Opinion about CELG-Q: (A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

stockchase.com stockchase.com

Bristol Myers Squibb (BMY-N)
The company has several blockbuster immunotherapy drugs in their pipeline, as well as some chemotherapy products for leukaemia. The company has announced plans to acquire Celgene that will add several other high profile drugs.

Bristol Myers Squibb (BMY-N) — Stockchase
Bristol Myers Squibb (BMY-N) — Stockchase

Opinion about BMY-N: You're betting on their drug pipeline.

stockchase.com stockchase.com

Pfizer Inc (PFE-N)
One of the largest pharmaceutical companies in the world. It is currently in its seasonal weakness which is mid-October. It has enjoyed long term support levels and is consolidating well.

Pfizer Inc (PFE-N) — Stockchase
Pfizer Inc (PFE-N) — Stockchase

Opinion about PFE-N: He owned it but sold. Free cash flow is not abundant and it has a lot of debt. It will take time to turn around but pays a good dividend.

stockchase.com stockchase.com

AbbVie Inc. (ABBV-N)
Their blood cancer drug is projected to be one of the top best selling drugs in the world in the near future. The company also has other oncology drugs such as a top-selling immunology drug called Humira. They are currently in the process of acquiring Allergan.

AbbVie Inc. (ABBV-N) — Stockchase
AbbVie Inc. (ABBV-N) — Stockchase

Opinion about ABBV-N: It's up over 8% this year, beating the market. The PE is 15x. Has consistent topline growth due to Skyrizi as well as Botox and arthritis. High-quality. Pays a 3.5% dividend.

stockchase.com stockchase.com

Johnson & Johnson (JNJ-N)
A global medical devices, pharmaceutical and consumer goods company. Their drugs are doing well and the company remains very profitable but volatile. They are going through a litigation for opiates and a ruling against their anti-psychotic drug.

Johnson & Johnson (JNJ-N) — Stockchase
Johnson & Johnson (JNJ-N) — Stockchase

Opinion about JNJ-N: High in 2022, series of lower highs and lower lows since then. Only positive is that on the most recent pullback it pulled back to a higher low. If you own it as one position among many, you probably won't lose a bunch of $$. Doesn't see it being a leading stock…

stockchase.com stockchase.com

Novartis AG (NVS-N)
One of the world’s largest pharmaceutical company based out of Switzerland. They sold off their ophthalmology business and are refocusing on generic drugs. The company also has many drugs that are close to approval that could become blockbuster drugs.

Novartis AG (NVS-N) — Stockchase
Novartis AG (NVS-N) — Stockchase

Opinion about NVS-N: If the economy slows down, you need a good pharma stock. Novartis was stuck in a rut until the current CEO started in 2018. He made a number of key acquisitions without paying and including smaller companies (they had overpaid in the past), focusing on their most lucrative divisions: drugs to treat…

stockchase.com stockchase.com

GlaxoSmithKline PLC (GSK-N)
A British pharma company that is refocusing away from consumer products to pharmaceuticals. The company is doing well with 5% dividend. However, there is a hard brexit risk.

GlaxoSmithKline PLC (GSK-N) — Stockchase
GlaxoSmithKline PLC (GSK-N) — Stockchase

Opinion about GSK-N: (A Top Pick Jan 16/25, Up 21.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with GSK has achieved its target at $41.  To remain disciplined, we recommend covering half the position at this time and maintaining the stop at $32.  

stockchase.com stockchase.com

Astrazeneca P L C (AZN-N)
A well diversified and global pharmaceutical company that specializes in oncology. They pay a great dividend and are focusing on less price-sensitive areas.

Astrazeneca P L C (AZN-N) — Stockchase
Astrazeneca P L C (AZN-N) — Stockchase

Opinion about AZN-N: Likes the pipeline. A number of candidates to seek approval in the next couple of years, which will be a catalyst for earnings going forward. Fairly productive R&D engine. Also growth through tuck-in acquisitions. Relatively attractively priced given current growth outlook. Going to be second-fastest growing drug stock in Europe behind NVO.…

stockchase.com stockchase.com

Gilead Sciences Inc. (GILD-Q)
An American biopharmaceutical company. They consolidated for the last year and a half. The company is doing well, with a 4% yield. They have a history of blockbuster drugs with Hepatitis C and HIV.

Gilead Sciences Inc. (GILD-Q) — Stockchase
Gilead Sciences Inc. (GILD-Q) — Stockchase

Opinion about GILD-Q: He had owned it for 10 years at a time when it had a blockbuster drug that cured hepatitis. Gilead took profits and invested them into HIV drugs. As with other drug companies holding patents on blockbuster drugs with expiry dates, don't buy this one.

stockchase.com stockchase.com

Regeneron Pharmaceuticals Inc (REGN-Q)
A biotech company with good free cash flow. They have some drugs for niche markets. Their earnings don’t come from one specific sector of their activity.

Regeneron Pharmaceuticals Inc (REGN-Q) — Stockchase
Regeneron Pharmaceuticals Inc (REGN-Q) — Stockchase

Opinion about REGN-Q: It's lost a third of its market cap and the selling is overdone. Now, is a buying opportunity.

stockchase.com stockchase.com

CRISPR Therapeutics AG (CRSP-Q)
A smaller company that is developing gene medications. They have a gene-editing tool that has the potential to cure several diseases, including some cancers.

CRISPR Therapeutics AG (CRSP-Q) — Stockchase
CRISPR Therapeutics AG (CRSP-Q) — Stockchase

Opinion about CRSP-Q: He sees this company mentioned in many science papers, but the stock has been a tough own. Overall, he likes it. Buy some now and more if it goes lower. How can this company keep losing money?

stockchase.com stockchase.com

Varian Medical Systems (VAR-N)
The company specializes in radiation therapy equipment to treat cancer. The trend for cancer radiation therapy is still positive and analysts think there will be an up-tick in sales.

Varian Medical Systems (VAR-N) — Stockchase
Varian Medical Systems (VAR-N) — Stockchase

Opinion about VAR-N: (A Top Pick Aug 29/14. Up 2.34%.) Radiation therapy equipment for treating cancer. Have been affected a little by foreign exchange rates. These are big ticket purchases, so she expects purchases have been delayed, but she has seen this come back. On the emerging-market side, it is a little bit more challenging.…

stockchase.com stockchase.com

Merck & Company (MRK-N)
Their main drugs are for treating diabetes and oncology. They have a great pipeline of new drugs that are coming up and will drive revenues over the long term. They pay a dividend of 2.65%

Merck & Company (MRK-N) — Stockchase
Merck & Company (MRK-N) — Stockchase

Opinion about MRK-N: Pharmas have not done well. MRK trades at 8x PE. They have one large drug, Keytruda, which makes up 46% of their revenues, which is risky. The chart looks terrible. But MRK has dozens of drugs in phase 2 and 3 trials. Also, this pays a fine dividend. Now is a fine…

stockchase.com stockchase.com

Eli Lilly & Co. (LLY-N)
A global pharmaceutical company that recently made an acquisition in oncology. It has been one of the best growth companies with a rate of 10% EPS.

Eli Lilly & Co. (LLY-N) — Stockchase
Eli Lilly & Co. (LLY-N) — Stockchase

Opinion about LLY-N: He trimmed. Is trading at 33x PE, down from 55x. Is the front runner in the GLP-1 business with 60% market share.

stockchase.com stockchase.com

Abbott Labs (ABT-N)
A diversified healthcare company. It sells generic drugs to emerging markets. They also have medical devices and are diversified globally. A very safe play, especially considering that they have raised dividends for 47 years straight. Yield of 1.50%.

Abbott Labs (ABT-N) — Stockchase
Abbott Labs (ABT-N) — Stockchase

Opinion about ABT-N: In general, he's had almost no healthcare exposure for the last year. Relative price performance for the group has been weak. That said, he's seeing some improvement around the edges. He always looks for what's held up better than the rest, and this name would fit. Performed better than 78% of S&P stocks…

stockchase.com stockchase.com

0
Shares
  • Share On Facebook
  • Tweet It




Trending Now
This Week's Stock Picks & BNN Top Picks Summary: SAN-N, DLO-Q and 18 Stock and 5 ETF Top Picks (Jun 06-12)
Melisa R. H. June 13, 2025
Weekly 52-Week Low (or 52-Week High): LBS-T, WDO-T, ESE-X, ARU-X and More 52-Week Highs and Lows (Jun 04-10)
Melisa R. H. June 11, 2025
Read Next

American markets were excited

  • logo

    We’re fintech passionates that reinvest almost all our revenues into the development of Stockchase and Wealthica. We hope you enjoy Stockchase and join Premium!

  • Top Reviews

    • Questrade Review: Pros & Cons of Trading with Questrade Canada (2023)
      8.5
    • The Ugly Truth About Identity Theft – Free Credit Report
      7
    • Questrade vs Others | The Review Competitors Don’t Want you to Read (2023)
  • Popular Posts

    • This Week's Stock Picks & BNN Top Picks Summary: SAN-N, DLO-Q and 18 Stock and 5 ETF Top Picks (Jun 06-12)
    • Weekly 52-Week Low (or 52-Week High): LBS-T, WDO-T, ESE-X, ARU-X and More 52-Week Highs and Lows (Jun 04-10)
    • Most Anticipated Earnings: DOL-T, TRZ-T and more Canadian Companies Reporting Earnings this Week (Jun 09-13)
  • Stock Lists

    • Unraveling 15 of the Best Natural Gas Stocks: A Canada-USA...
      November 10, 2023
    • 13 Recession-Proof Stocks for Portfolio Safety
      October 26, 2023
    • The Ultimate Top Drone Stocks List for Sky-High Returns...
      October 25, 2023
    • Top Hotel Stocks to Buy for your Growth Portfolio
      October 12, 2023
    • Which Brookfield Stock to Buy? BAM vs BN: the Inspiring...
      October 9, 2023



  • Stockchase neither recommends nor promotes any investment strategies.

    About us : Privacy & Terms : Contact us

© Stockchase Inc.
Press enter/return to begin your search